The Immunogenicity and the Safety of the Adjuvanted Glycoprotein E (GE)-Based Recombinant Vaccine Against Herpes Zoster (RZV) in Cancer Patients During Immunotherapy

Investigators described the humoral and cell-mediated immune responses in 38 cancer patients treated with immune checkpoint inhibitors and receiving the glycoprotein E-based recombinant vaccine.